+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Decreased vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) function in knockout mice affects aging of dopaminergic systems

Decreased vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) function in knockout mice affects aging of dopaminergic systems

Neuropharmacology 76 Pt A: 146-155

Dopamine (DA) is accumulated and compartmentalized by the dopamine transporter (DAT; SLC3A6) and the vesicular monoamine transporter 2 (VMAT2; SLC18A2). These transporters work at the plasma and vesicular membranes of dopaminergic neurons, respectively, and thus regulate levels of DA in neuronal compartments that include the extravesicular cytoplasmic compartment. DA in this compartment has been hypothesized to contribute to oxidative damage that can reduce the function of dopaminergic neurons in aging brains and may contribute to reductions in dopaminergic neurochemical markers, locomotor behavior and responses to dopaminergic drugs that are found in aged animals. The studies reported here examined aged mice with heterozygous deletions of VMAT2 or of DAT, which each reduce transporter expression to about 50% of levels found in wild-type (WT) mice. Aged mice displayed reduced locomotor responses under a variety of circumstances, including in response to locomotor stimulants, as well as changes in monoamine levels and metabolites in a regionally dependent manner. Several effects of aging were more pronounced in heterozygous VMAT2 knockout (KO) mice, including aging induced reductions in locomotion and reduced locomotor responses to cocaine. By contrast, some effects of aging were reduced or not observed in heterozygous DAT KO mice. These findings support the idea that altered DAT and VMAT2 expression affect age-related changes in dopaminergic function. These effects are most likely mediated by alterations in DA compartmentalization, and might be hypothesized to be exacerbated by other factors that affect the metabolism of cytosolic DA. This article is part of the Special Issue entitled 'The Synaptic Basis of Neurodegenerative Disorders'.

Please choose payment method:

(PDF emailed within 0-6 h: $19.90)

Accession: 052462737

Download citation: RISBibTeXText

PMID: 23978383

DOI: 10.1016/j.neuropharm.2013.07.031

Related references

Sex-dependent modulation of ethanol consumption in vesicular monoamine transporter 2 (VMAT2) and dopamine transporter (DAT) knockout mice. Neuropsychopharmacology 28(4): 620-628, 2003

Aging effects on locomotor activity in dopamine transporter and vesicular monoamine transporter knockout mice. Society for Neuroscience Abstracts 26(1-2): Abstract No -344 5, 2000

Rapid and differential losses of in vivo dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) radioligand binding in MPTP-treated mice. Synapse 35(4): 250-255, 2000

Oestrogens prevent loss of dopamine transporter (DAT) and vesicular monoamine transporter (VMAT2) in substantia nigra of 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine mice. Journal of Neuroendocrinology 17(8): 509-517, 2005

Dopamine transporter and vesicular monoamine transporter knockout mice : implications for Parkinson's disease. Methods in Molecular Medicine 62: 179-190, 2001

Dopamine D1, D2, D3 receptors, vesicular monoamine transporter type-2 (VMAT2) and dopamine transporter (DAT) densities in aged human brain. Plos one 7(11): E49483, 2012

Coordinated expression of dopamine transporter DAT and vesicular monoamine transporter VMAT2 in the primate striatum during development. 2013

New insights into the mechanism of methamphetamine neurotoxicity as revealed by dopamine transporter knockout mice and mice heterozygous for vesicular monoamine transporter 2. Society for Neuroscience Abstracts 24(1-2): 610, 1998

No differential regulation of dopamine transporter (DAT) and vesicular monoamine transporter 2 (VMAT2) binding in a primate model of Parkinson disease. Plos one 7(2): E31439, 2012

Genetic deletion of vesicular monoamine transporter-2 (VMAT2) reduces dopamine transporter activity in mesencephalic neurons in primary culture. Neurochemistry International 51(2-4): 237-244, 2007

Increased Vesicular Monoamine Transporter 2 (VMAT2) and Dopamine Transporter (DAT) Expression in Adolescent Brain Development: A Longitudinal Micro-PET/CT Study in Rodent. Frontiers in Neuroscience 12: 1052, 2018

Presynaptic control of striatal dopamine neurotransmission in adult vesicular monoamine transporter 2 (VMAT2) mutant mice. Journal of Neurochemistry 85(4): 898-910, 2003

Norepinephrine transporter (NET), serotonin transporter (SERT), vesicular monoamine transporter (VMAT2) and organic cation transporters (OCT1, 2 and EMT) in human placenta from pre-eclamptic and normotensive pregnancies. Placenta 25(6): 518-529, 2004

The vesicular monoamine transporter VMAT2 and vesicular acetylcholine transporter VAChT are sorted to separate vesicle populations in PC12 cells. Advances in Pharmacology 42: 250-253, 1998

Dopamine transporter and synaptic vesicular monoamine transporter expression and Parkinsons disease dopaminergic damage. Neurology 44(4 Suppl. 2): A282, 1994